文献速递冠心病

院前床旁肌钙蛋白对疑似NSTE-ACS风险分层的个体患者数据荟萃分析

Prehospital risk stratification in suspected non-ST-segment elevation acute coronary syndrome with point-of-care troponin: an individual patient data meta-analysis.
PubMed 文献 · Heart · 2026-09-11

低风险分层预测30天全因死亡的敏感度93.2%、阴性预测值99.8%,预测死亡和/或AMI及MACE的敏感度与NPV亦较高;降低低风险 cutoff 可提高敏感度与NPV但减少低风险患者比例。

要点

  • HEART衍生风险评分在训练有素的EMS系统中可有效识别30天死亡和MACE极低风险患者。
  • 低风险分层对30天全因死亡的敏感度93.2%、NPV 99.8%。
  • 在其他医疗体系实施前需额外验证,因医疗结构、分层流程和随访能力存在差异。

核心结论

  • 在训练有素的EMS系统中,HEART衍生临床风险评分能有效识别30天死亡和MACE风险极低的疑似NSTE-ACS患者。
  • 在其他医疗体系实施需额外验证,因医疗结构、风险分层流程和随访能力存在差异。

研究设计与样本

  • 系统评价与个体患者数据荟萃分析,纳入在EMS环境中使用临床风险评分或床旁肌钙蛋白对疑似NSTE-ACS患者进行风险分层的前瞻性研究。

主要发现

  • 低风险临床风险评分预测30天全因死亡的敏感度为93.2%(83.5-98.1),NPV为99.8%(99.5-99.9)。
  • 预测30天死亡和/或AMI的敏感度为91.8%(83.0-96.2),NPV为97.3%(89.9-99.3)。
  • 预测30天MACE的敏感度为92.8%(88.7-95.5),NPV为97.2%(92.1-99.0)。
  • 降低识别低风险患者的临床风险评分 cutoff 值可提高敏感度和NPV,但减少被归类为低风险的患者比例。

关键数值与推荐

  • 低风险定义基于临床风险评分或床旁肌钙蛋白测量。
  • 评估的安全性是低风险患者30天内全因死亡、死亡和/或AMI复合终点、MACE的敏感度和阴性预测值。

临床怎么用

  • 在训练有素且能对低风险患者进行及时准确随访的EMS系统中,可使用HEART衍生临床风险评分进行院前风险分层。
  • 在其他医疗体系应用前,需考虑医疗结构、风险分层流程和随访能力的差异并进行额外验证。

局限性

  • 纳入研究均使用HEART评分衍生的临床风险评分,其他评分的证据有限。
  • 实施于其他医疗体系需额外验证,因医疗结构、风险分层流程和随访能力存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Emergency Medical Services (EMS) patients with chest pain are often suspected of having non-ST-elevation acute coronary syndrome (NSTE-ACS). Current risk stratification protocols for NSTE-ACS have limitations, leading to a lack of a well-organised prehospital diagnostic pathway. Recent studies have demonstrated that using clinical risk scores (CRS) including point-of-care (POC)-troponin in the EMS can improve prehospital diagnostic pathways for suspected NSTE-ACS. The primary aim of this systematic review and individual patient data meta-analysis was to assess safety of low-risk stratification for suspected NSTE-ACS patients in the prehospital setting. METHODS: Prospective studies using CRS or POC-troponin for risk stratification in suspected NSTE-ACS patients within the EMS setting were included. Safety was assessed using sensitivity and negative predictive value (NPV) for patients identified as low risk, based on CRS or POC-troponin measurement, for three different endpoints within 30 days: (1) all-cause mortality, (2) composite of mortality and/or acute myocardial infarction (AMI), (3) major adverse cardiac events (MACE). RESULTS: Of 1526 articles screened, 6 were included, comprising 5.239 patients, and all utilised CRS derived from the History, ECG, Age, Risk-factor and Troponin (HEART) score. The summary of low-risk CRS diagnostic performance predicted all-cause mortality with a sensitivity of 93.2% (83.5-98.1) and NPV of 99.8% (99.5-99.9); mortality and/or AMI with a sensitivity of 91.8% (83.0-96.2) and an NPV of 97.3% (89.9-99.3); and MACE with a sensitivity of 92.8% (88.7-95.5) and an NPV of 97.2% (92.1-99.0). Lowering the CRS cut-off value for identifying low-risk patients increased sensitivity and NPV but decreased the proportion of patients classified as low risk. CONCLUSION: In well-trained EMS systems, where prompt and accurate follow-up of low-risk patients is possible, HEART-derived CRS effectively identify patients with a very low risk of 30-day mortality and MACE. However, implementation in other healthcare systems requires additional validation, given the variations in healthcare structure, risk stratification processes and follow-up capabilities.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Demandt, Sagel, Camaro, et al. Prehospital risk stratification in suspected non-ST-segment elevation acute coronary syndrome with point-of-care troponin: an individual patient data meta-analysis. Heart. 2026. PMID: 41482474. doi:10.1136/heartjnl-2025-326922

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。